Chronic hepatitis B infection is a major health burden in Asia, because at least three quarters of the 300 million Hepatitis B s Antigen (HBsAg)-positive individuals worldwide live in there. The main objective of treating chronic Hepatitis B Virus (HBV) infection is to reduce HBV replication since continued replication will result in the progression of liver disease. The suppression of replication can be monitored by the loss of HBV DNA by hybridization and the loss of Hepatitis B e Antigen (HBeAg). However, since the loss of HBsAg and HBV DNA as assayed by Polymerase Chain Reaction (PCR) is very difficult to achieve, it is not an ideal objective (Lai and Yuen, 1997).